Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Fate Therapeutics Inc (FATE)  
$3.90 0.20 (5.41%) as of 4:30 Thu 5/9


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 118,506,000
Market Cap: 462.17(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $1.65 - $8.35
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    : 7.7
Insider 3/6 Months : 8.3
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 44,630 44,630 471,648
Total Buy Value $0 $166,024 $166,024 $2,724,191
Total People Bought 0 1 1 2
Total Buy Transactions 0 1 1 6
Total Shares Sold 2,447 78,990 96,836 590,364
Total Sell Value $19,013 $301,730 $380,390 $5,527,958
Total People Sold 1 4 6 14
Total Sell Transactions 1 9 14 36
End Date 2024-02-08 2023-11-07 2023-05-09 2022-05-09

   
Records found: 297
  Page 7 of 12  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Dulac Edward J Iii Chief Financial Officer   •       –      –    2021-01-20 4 A $0.00 $0 D/D 18,013 58,013     -
   Shoemaker Daniel D Chief Scientific Officer   •       –      –    2021-01-20 4 A $0.00 $0 D/D 14,411 98,020     -
   Valamehr Bahram Chief Development Officer   •       –      –    2021-01-20 4 A $0.00 $0 D/D 18,013 95,740     -
   Tahl Cindy General Counsel and Secretary   •       –      –    2021-01-20 4 A $0.00 $0 D/D 18,013 108,048     -
   Tahl Cindy General Counsel and Secretary   •       –      –    2021-01-19 4 AS $114.11 $4,016,639 D/D (35,000) 90,035 -33%     
   Tahl Cindy General Counsel and Secretary   •       –      –    2021-01-19 4 OE $2.90 $101,500 D/D 35,000 125,035     -
   Wolchko J Scott President and CEO   •       •      –    2021-01-11 4 S $109.65 $951,556 D/D (8,587) 350,562 31%     
   Valamehr Bahram Chief Development Officer   •       –      –    2021-01-11 4 S $109.65 $360,588 D/D (3,254) 77,727 31%     
   Tahl Cindy General Counsel and Secretary   •       –      –    2021-01-11 4 S $109.65 $360,587 D/D (3,254) 90,035 31%     
   Shoemaker Daniel D Chief Scientific Officer   •       –      –    2021-01-11 4 S $109.65 $360,477 D/D (3,253) 83,609 31%     
   Green Jeremy Director   –       •       •   2021-01-08 4 B $85.50 $27,999,968 I/I 327,485 12,957,222 2.25 -35%     
   Wolchko J Scott President and CEO   •       •      –    2021-01-08 4 S $114.76 $7,122,217 D/D (60,820) 359,149 35%     
   Valamehr Bahram Chief Development Officer   •       –      –    2021-01-08 4 S $114.76 $729,552 D/D (6,230) 80,981 35%     
   Tahl Cindy General Counsel and Secretary   •       –      –    2021-01-08 4 S $114.76 $729,434 D/D (6,229) 93,289 35%     
   Shoemaker Daniel D Chief Scientific Officer   •       –      –    2021-01-08 4 S $114.76 $729,434 D/D (6,229) 86,862 35%     
   Wolchko J Scott President and CEO   •       •      –    2020-12-17 4 AS $90.98 $1,836,352 D/D (20,000) 419,969 -7%     
   Wolchko J Scott President and CEO   •       •      –    2020-12-17 4 OE $6.62 $132,400 D/D 20,000 439,969     -
   Valamehr Bahram Chief Development Officer   •       –      –    2020-12-14 4 AS $95.89 $2,444,477 D/D (25,000) 87,211 -5%     
   Valamehr Bahram Chief Development Officer   •       –      –    2020-12-14 4 OE $2.90 $72,500 D/D 25,000 112,211     -
   Shoemaker Daniel D Chief Scientific Officer   •       –      –    2020-11-16 4 AS $50.37 $1,295,746 D/D (25,000) 93,091 38%     
   Wolchko J Scott President and CEO   •       •      –    2020-11-13 4 AS $51.03 $1,530,900 D/D (30,000) 419,969 43%     
   Wolchko J Scott President and CEO   •       •      –    2020-11-13 4 OE $2.73 $172,008 D/D 30,000 430,123     -
   Wolchko J Scott President and CEO   •       •      –    2020-11-12 4 AS $51.61 $1,581,524 D/D (30,000) 419,969 51%     
   Wolchko J Scott President and CEO   •       •      –    2020-11-12 4 OE $2.73 $81,900 D/D 30,000 449,969     -
   Tahl Cindy General Counsel and Secretary   •       –      –    2020-11-05 4 AS $50.55 $976,252 D/D (19,282) 99,518 72%     
  297 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 7 of 12
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us